UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Clinical therapeutics, 2007, Vol.29 (1), p.139-153

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

The New England journal of medicine, 1998-03, Vol.338 (13), p.867-873

1998

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes

Diabetes care, 2002-04, Vol.25 (4), p.724-730

2002

Link zum Volltext

Verfügbarkeit prüfen

Striking Differences in Glucose and Lactate Levels Between Brain Extracellular Fluid and Plasma in Conscious Human Subjects: Effects of Hyperglycemia and Hypoglycemia

Journal of cerebral blood flow and metabolism, 2002-03, Vol.22 (3), p.271-279

2002

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Efficacy and Safety Data of Exenatide Once Weekly

Mayo Clinic proceedings, , Vol.90 (3), p.356-365

Link zum Volltext

Verfügbarkeit prüfen

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Current medical research and opinion, 2008-01, Vol.24 (1), p.275-286

2008

Link zum Volltext

Verfügbarkeit prüfen

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial

Mayo Clinic proceedings, 2015-03, Vol.90 (3), p.356-365

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes

Diabetes care, 2005-03, Vol.28 (3), p.632-637

2005

Link zum Volltext

Verfügbarkeit prüfen

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes : A 1-year randomized controlled trial

Diabetes care, 2003-03, Vol.26 (3), p.784-790

2003

Link zum Volltext

Verfügbarkeit prüfen

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials

Advances in therapy, 2016-05, Vol.33 (5), p.848-861

2016

Link zum Volltext

Verfügbarkeit prüfen

Incretin-based therapies

Journal of diabetes, 2012-03, Vol.4 (1), p.55-67

2012

Link zum Volltext

Verfügbarkeit prüfen

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

Obesity (Silver Spring, Md.), 2004-04, Vol.12 (4), p.661-668

2004

Link zum Volltext

Verfügbarkeit prüfen

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Diabetes/metabolism research and reviews, 2006-11, Vol.22 (6), p.483-491

2006

Link zum Volltext

Verfügbarkeit prüfen

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing study

Diabetes care, 2003-11, Vol.26 (11), p.3074-3079

2003

Link zum Volltext

Verfügbarkeit prüfen

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

Diabetes care, 2003, Vol.26 (1), p.1-8

2003

Link zum Volltext

Verfügbarkeit prüfen

Effect of insulin on glycerol production in obese adolescents

American journal of physiology: endocrinology and metabolism, 1998-04, Vol.274 (4), p.E737-E743

1998

Link zum Volltext

Verfügbarkeit prüfen

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

Diabetes/metabolism research and reviews, 2004-01, Vol.20 (1), p.55-60

2004

Link zum Volltext

Verfügbarkeit prüfen

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Current medical research and opinion, 2008-01, Vol.24 (1), p.275-286

2008

Link zum Volltext

Verfügbarkeit prüfen

Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue

Diabetes (New York, N.Y.), 1997-01, Vol.46 (1), p.70

1997

Link zum Volltext

Verfügbarkeit prüfen

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

Annals of internal medicine, 1998-02, Vol.128 (3), p.176

1998

Link zum Volltext

Verfügbarkeit prüfen

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

Diabetes care, 2003-11, Vol.26 (11), p.3074-3079

2003

Link zum Volltext

Verfügbarkeit prüfen

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Diabetes care, 2003-03, Vol.26 (3), p.784-790

2003

Link zum Volltext

Verfügbarkeit prüfen

Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy

Clinical diabetes, 2002-07, Vol.20 (3), p.137-144

2002

Link zum Volltext

Verfügbarkeit prüfen

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes

Diabetes, obesity & metabolism, 2005-09, Vol.7 (5), p.504-516

2005

Link zum Volltext

Verfügbarkeit prüfen

Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle

The Journal of clinical investigation, 1995-07, Vol.96 (1), p.370-377

1995

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(43)
Humans
(34)
Male
(32)
Female
(31)
Middle Aged
(20)
Adult
(17)
Aged
(15)
Biological And Medical Sciences
(15)
Medical Sciences
(14)
Endocrinology & Metabolism
(13)
Type 2 Diabetes
(13)
Diabetes Mellitus, Type 2 - Drug Therapy
(12)
Insulin
(12)
Blood Glucose - Metabolism
(11)
Diabetes
(11)
Drug Therapy
(10)
Drug Therapy, Combination
(10)
Hypoglycemic Agents - Therapeutic Use
(10)
Blood Glucose - Drug Effects
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes

Striking Differences in Glucose and Lactate Levels Between Brain Extracellular Fluid and Plasma in Conscious Human Subjects: Effects of Hyperglycemia and Hypoglycemia

Five-Year Efficacy and Safety Data of Exenatide Once Weekly

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes : A 1-year randomized controlled trial

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials

Incretin-based therapies

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing study

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

Effect of insulin on glycerol production in obese adolescents

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes

Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle

Suchergebnisse filtern